Cocrystal Pharma, Inc. (NASDAQ:COCP) Short Interest Update

Cocrystal Pharma, Inc. (NASDAQ:COCP) saw a large decrease in short interest during the month of April. As of April 30th, there was short interest totaling 586,422 shares, a decrease of 40.7% from the April 15th total of 988,346 shares. Based on an average trading volume of 189,024 shares, the short-interest ratio is presently 3.1 days. Approximately 5.9% of the shares of the stock are sold short.

Cocrystal Pharma Price Performance

Shares of NASDAQ:COCP traded up $0.03 on Monday, reaching $1.23. 109,838 shares of the company traded hands, compared to its average volume of 1,635,299. Cocrystal Pharma has a fifty-two week low of $0.86 and a fifty-two week high of $2.67. The company’s 50 day moving average is $1.27 and its 200-day moving average is $1.11. The stock has a market capitalization of $16.96 million, a PE ratio of -1.68 and a beta of 1.50.

Cocrystal Pharma (NASDAQ:COCP) last announced its quarterly earnings data on Thursday, May 21st. The company reported ($0.17) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). The firm had revenue of $0.22 million during the quarter. As a group, analysts expect that Cocrystal Pharma will post -0.67 EPS for the current year.

Institutional Trading of Cocrystal Pharma

A hedge fund recently bought a new stake in Cocrystal Pharma stock. T3 Companies LLC bought a new stake in shares of Cocrystal Pharma, Inc. (NASDAQ:COCP) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The fund bought 52,300 shares of the company’s stock, valued at approximately $51,000. T3 Companies LLC owned 0.38% of Cocrystal Pharma as of its most recent SEC filing. Institutional investors own 6.72% of the company’s stock.

About Cocrystal Pharma

Cocrystal Pharma, Inc (NASDAQ:COCP) is a clinical-stage biotechnology company focused on the discovery and development of novel antiviral therapeutics. Utilizing an integrated structure-guided drug design platform, the company combines x-ray crystallography, computational chemistry and medicinal chemistry to identify and optimize small molecule inhibitors targeting key viral enzymes. This approach is intended to accelerate the progression of lead candidates from discovery through preclinical development.

The company’s pipeline includes multiple preclinical programs aimed at treating respiratory and systemic viral infections.